Literature DB >> 30292421

Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.

Sophie Knipper1, Derya Tilki2, Joost Mansholt1, Christoph Berliner3, Christian Bernreuther3, Thomas Steuber1, Tobias Maurer1, Markus Graefen1.   

Abstract

The first results on 99mTechnetium prostate-specific membrane antigen-radioguided surgery (99mTc-PSMA- RGS) showed promising outcome. Here, we sought to evaluate if this targeted molecular surgical approach might be more effective than conventional salvage lymph node dissection (sLND). We prospectively analysed 42 consecutive patients who underwent sLND based on preoperative 68Gallium (68Ga)-PSMA-positron emission tomography (PET) imaging between 2015 and 2018. In 29 patients, the dissection field was based solely 68Ga-PSMA-PET imaging (conventional surgical approach [CSA]), whereas 13 patients underwent 99mTc-PSMA-RGS. Preoperative characteristics of both groups were similar. Final pathology revealed no metastases in nine CSA patients (31%), whereas all visible lesions on preoperative 68Ga-PSMA-PET were removed in patients who underwent RGS. A PSA decline in general, >50% and >90% within 6 wk was seen in 50%, 29%, and 7% versus 100%, 92%, and 53% in CSA versus RGS groups, respectively (all p<0.01). This is the first comparison of conventional and PSMA-radioguided approach with regards to short-term efficacy of sLND. Although long-term outcome needs to be awaited, RGS offers promising results. PATIENT
SUMMARY: We compared two surgical approaches for lymph node dissection in lymph node only recurrent prostate cancer patients. The radioguided approach was superior in removing the affected lymph nodes, resulting in a more pronounced prostate-specific antigen decline.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lymph node recurrent disease; PSMA-PET; PSMA-radioguided surgery; Prostate cancer; Salvage lymph node dissection

Mesh:

Substances:

Year:  2018        PMID: 30292421     DOI: 10.1016/j.euf.2018.09.014

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  8 in total

Review 1.  [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?]

Authors:  T Steuber; T Maurer; K Miller
Journal:  Urologe A       Date:  2021-11-03       Impact factor: 0.639

Review 2.  Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.

Authors:  George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

Review 3.  Advances in PSMA-targeted therapy for prostate cancer.

Authors:  Fujin Wang; Zhifeng Li; Xiaoqian Feng; Dazhuang Yang; Mei Lin
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-28       Impact factor: 5.554

4.  Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.

Authors:  Carlo A Bravi; Nicola Fossati; Giorgio Gandaglia; Nazareno Suardi; Elio Mazzone; Daniele Robesti; Daniar Osmonov; Klaus-Peter Juenemann; Luca Boeri; R Jeffrey Karnes; Alexander Kretschmer; Alexander Buchner; Christian Stief; Andreas Hiester; Alessandro Nini; Peter Albers; Gaëtan Devos; Steven Joniau; Hendrik Van Poppel; Shahrokh F Shariat; Axel Heidenreich; David Pfister; Derya Tilki; Markus Graefen; Inderbir S Gill; Alexander Mottrie; Pierre I Karakiewicz; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2020-07-02       Impact factor: 24.267

Review 5.  Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection.

Authors:  Marieke J Krimphove; Lena H Theissen; Alexander P Cole; Felix Preisser; Philipp C Mandel; Felix K H Chun
Journal:  World J Mens Health       Date:  2019-03-05       Impact factor: 5.400

6.  Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design.

Authors:  Alexander Kretschmer; Johanna Milow; Chukwuka Eze; Alexander Buchner; Minglun Li; Thilo Westhofen; Frederik Fuchs; Paul Rogowski; Christian Trapp; Ute Ganswindt; Mathias Johannes Zacherl; Leonie Beyer; Vera Wenter; Peter Bartenstein; Boris Schlenker; Christian G Stief; Claus Belka; Nina-Sophie Schmidt-Hegemann
Journal:  Front Oncol       Date:  2021-06-21       Impact factor: 6.244

7.  PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis.

Authors:  Nina-Sophie Schmidt-Hegemann; Alexander Buchner; Chukwuka Eze; Paul Rogowski; Christian Schaefer; Harun Ilhan; Minglun Li; Wolfgang Peter Fendler; Peter Bartenstein; Ute Ganswindt; Christian Stief; Claus Belka; Alexander Kretschmer
Journal:  Strahlenther Onkol       Date:  2020-03-24       Impact factor: 3.621

Review 8.  PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.

Authors:  Yvonne H W Derks; Dennis W P M Löwik; J P Michiel Sedelaar; Martin Gotthardt; Otto C Boerman; Mark Rijpkema; Susanne Lütje; Sandra Heskamp
Journal:  Theranostics       Date:  2019-09-20       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.